Athira Pharma Inc
Change company Symbol lookup
Select an option...
ATHA Athira Pharma Inc
CEVIY China Everbright Ltd
PATK Patrick Industries Inc
TGHI Touchpoint Group Holdings Inc
PIAI^ Prime Impact Acquisition I
CGEN Compugen Ltd
FPAY FlexShopper Inc
IOACW Innovative International Acquisition Equity Warrants Exp 26th Oct 2026 *W EXP 10/26/2026
FUSN Fusion Pharmaceuticals Inc
COUR Coursera Inc
Go

Health Care : Pharmaceuticals |
Company profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.

Closing Price
$3.90
Day's Change
0.15 (4.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.00
Day's Low
3.77
Volume
(Light)
Volume:
342,544

10-day average volume:
453,880
342,544

Company Profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
0.48x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2022
Current Month
1.8M
Previous Month
2.0M
Percent of Float
5.73%
Days to Cover
3.7089 Days

Share Information

ATHA is in a share class of common stock
Float
35.7M
Shares Outstanding
37.6M
Institutions Holding Shares
135
76.48%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Kelly A. Romano
  • Mark James LittonPres.
  • Glenna MilesonCFO
  • Rachel LeningtonCOO
  • Kevin ChurchExec.VP

Address

Insider Trading

During the most recent quarter, 1M shares were bought, and 20K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.